Mo.Re. (Molecular Response) is multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Understanding the unique biology of each patient’s tumor can assist in providing individualized treatment options. The development of a new technology called Next Generation Sequencing or NGS, allows us today to analyze multiple genes from the same sample simultaneously.
This breakthrough technology along with cloud computing and bioinformatics work together in order to analyze massive volumes of data from the patients’ genome and transform it in an actionable report providing information on three main categories of results which are:
Why choose Mo.Re?
Mo.Re. is a widely validated assay that has been selected by the National Cancer Institute in the United States, as the assay of choice for stratifying more than 3000 patients that participate in the MATCH (Molecular Analysis for Therapy Choice) Clinical Trial to assign to them targeted treatments. MATCH is the first multi-centric clinical study where the targeted therapeutic approach is based on the molecular pathway analysis of the tumor, independently of the organ of origin. Mo.Re. is designed to help physicians select the appropriate targeted treatments for their patients and avoid the toxicity and other side effects of chemotherapy, especially in cases where a conventional therapy has already been used with limited response and in some cases even resistance.
Mo.Re is designed in order to allow you and your physician to select which is the optimal targeted treatment based on your unique tumor biology.
This test is designed for the following cases:
| 147 Gene Alterations | ||||||
|---|---|---|---|---|---|---|
| AKT1 | CDK12 | FANCA | IDH2 | MSH2 | PIK3CA | RICTOR |
| AKT2 | CDK2 | FANCD2 | IGF1R | MSH6 | PIK3CB | RNF43 |
| AKT3 | CDK4 | FANCI | JAK1 | MTOR | PIK3R1 | ROS1 |
| ALK | CDK6 | FBXW7 | JAK2 | MYC | PMS2 | SETD2 |
| AR | CDKN1B | FGF19 | JAK3 | MYCL | POLE | SF3B1 |
| ARAF | CDKN2A | FGF3 | KDR | MYCN | PPARG | SLX4 |
| ARID1A | CDKN2B | FGFR1 | KIT | MYD88 | PPP2R1A | SMAD4 |
| ATM | CHEK1 | FGFR2 | KNSTRN | NBN | PTCH1 | SMARCA4 |
| ATR | CHEK2 | FGFR3 | KRAS | NF1 | PTEN | SMARCB1 |
| ATRX | CREBBP | FGFR4 | MAGOH | NF2 | PTPN11 | SMO |
| AXL | CSF1R | FLT3 | MAP2K1 | NFE2L2 | RAC1 | SPOP |
| BAP1 | CTNNB1 | FOXL2 | MAP2K2 | NOTCH1 | RAD50 | SRC |
| BRAF | DDR2 | GATA2 | MAP2K4 | NOTCH2 | RAD51 | STAT3 |
| BRCA1 | EGFR | GNA11 | MAPK1 | NOTCH3 | RAD51B | STK11 |
| BRCA2 | ERBB2 | GNAQ | MAX | NRAS | RAD51C | TERT |
| BTK | ERBB3 | GNAS | MDM2 | NTRK1 | RAD51D | TOP1 |
| CBL | ERBB4 | H3F3A | MDM4 | NTRK2 | RAF1 | TP53 |
| CCND1 | ERCC2 | HIST1H3B | MED12 | NTRK3 | RB1 | TSC1 |
| CCND2 | ESR1 | HNF1A | MET | PALB2 | RET | TSC2 |
| CCND3 | ESR1 | HRAS | MLH1 | PDGFRA | RHEB | U2AF1 |
| CCNE1 | EZH2 | IDH1 | MRE11A | PDGFRB | RHOA | XPO1 |
| 51 fusion transcripts | ||||||
| AKT2 | ALK | AR | AXL | BRAF | BRCA1 | BRCA2 |
| CDKN2A | EGFR | ERBB2 | ERBB4 | ERG | ESR1 | ETV1 |
| ETV4 | ETV5 | FGFR1 | FGFR2 | FGFR3 | FGR | FLT3 |
| JAK2 | KRAS | MDM4 | MET | MYB | MUBL1 | NF1 |
| NOTCH1 | NOTCH4 | NRG1 | NTRK1 | NTRK2 | NTRK3 | NUTM1 |
| PDGFRA | PDGFRB | PIK3CA | PPARG | PRKACA | PRKACB | PTEN |
| RAD51B | RAF1 | RB1 | RELA | RET | ROS1 | RSPO2 |
| RSPO3 | TERT | |||||
Mo.Re. provides valuable information that can be utilized to select the optimal targeted treatment for patients. By analyzing many genes at the same time it provides a detailed blueprint of the biology of the tumor, which is used by the treating physician to design the patient’s treatment plan.
An individualized report that summarizes the findings of biology of your tumor is provided to you and your physician. <
GeneKor takes care of all the logistics in order for your sample to arrive to our laboratory safely.
Our team of experts is here to interpret your results to you and your treating physician.
It is designed for all types of solid tumors including those of unknown origin.
The results of the Mo.Re. Assay will be available in 15 working days.
For the Mo.Re. Assay we need a paraffin block that contains the tumor tissue. We need one paraffin block or four unstained paraffin sections of 3μm: in positive charged slides (air dried, not baked), placed on top of the slide, without folds and six unstained slides of 10μm.
The sample should be kept at room temperature (25°C). During the summer period we recommend to have an ice pack in the Kit (The ice pack should not directly touch the sample).
For information about the cost coverage of the test you should contact your personal insurance.
The payment can be made by bank transfer or credit/debit card.
Genekor is responsible for all the necessary procedures of the pick-up and return of the patient’s specimen. To arrange your sample pick-up and return, contact us or complete the Test Order Form.
Your results will be shared with the ordering physician via e-mail.
Genekor Medical S.A. is certified with ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012, which require the written consent of each patient for the use of his/her genetic material for testing.
Ask your physician if you are eligible for the Mo.Re. test
Tissue from surgery or biopsy which is embedded in paraffin (FFPET) is required for this test. Your sample will be collected per your physicans' instructions
Your sample will arrive to our accredited laboratory and your report will be generated and released to you and your physician in 15 working days
Your report will be electronically released to your physician via email and/or uplaoded to our secure portal, and to you via email or mail
Mo.Re. is designed in order to achieve the highest sensitivity and specificity. All findings are classified using the most reliable and updated databases and in silico analysis algorithms. Advanced Next Generation Sequencing technology, also known as NGS, is used to fully analyze a panel of genes that are related to targeted treatments. The assay analyzes both DNA and RNA and looks at all possible gene alterations.
For more scientific and technical information you can contact us: scientific.support@genekor.com
